As an AR inhibitor, Enz can reduce the proliferation and death of prostate cancer cells [45, 46], and it also can block the malignant progression caused by AR-mediated LINC01503 in NPC, which may provide a potential drug target for individualized treatment of NPC patients. This evidence concerns the gene AR and nasopharyngeal carcinoma.